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DOI 10.1016/j.ccr.2009.12.049SUMMARYThe neural stem cell marker CD133 is reported to identify cells within glioblastoma (GBM) that can initiate
neurosphere growth and tumor formation; however, instances of CD133 cells exhibiting similar properties
have also been reported. Here, we show that some PTEN-deficient GBM tumors produce a series of CD133+
and CD133 self-renewing tumor-initiating cell types and provide evidence that these cell types constitute
a lineage hierarchy. Our results show that the capacities for self-renewal and tumor initiation in GBM need
not be restricted to a uniform population of stemlike cells, but can be shared by a lineage of self-renewing
cell types expressing a range of markers of forebrain lineage.INTRODUCTION
The concept that human malignancies are relentlessly fueled by
identifiable subpopulations of tumor cells with unlimited capacity
for self-renewal has important therapeutic implications, yet
remains a hotly debated issue (Clarke et al., 2006; Sakariassen
et al., 2007). Some proponents of the so-called ‘‘cancer stem
cell theory’’ suggest that effective therapeutic targeting of self-
renewing tumor cells at the apex of a lineage hierarchy might
eradicate the capacity for prolonged tumor growth (Korkaya
and Wicha, 2007). Human GBM is an aggressive malignancy
characterized by marked intra- and intertumoral heterogeneity.
Although the neural stem cell marker CD133 has been demon-Significance
Increasing controversy surrounds the concept that identifiable
are selectively critical for the relentless growth of many human
status and lineage relationships in determining GBM cell comp
of phenotypically distinct self-renewing cell types that promot
demonstrate that individual GBM tumors can contain both CD
tumors. These findings suggest that optimal treatment of GBM
cell populations expressing a range of phenotypic markers.
362 Cancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc.strated to demarcate GBM cells exhibiting enhanced competen-
cies for self-renewal and tumor initiation (Bao et al., 2006; Singh
et al., 2004), instances in which CD133 cells exhibit similar
properties have been reported (Beier et al., 2007; Joo et al.,
2008; Ogden et al., 2008; Wang et al., 2008). Because existing
studies examining tumor-initiating capabilities of human GBM
cells rely on cell-sorting techniques that result in impure cell frac-
tions, it is difficult to draw definitive conclusions on the capabil-
ities of GBM cells as a function of CD133 expression. Thus, it is
not clear to what extent GBM cells with the capacity for long-
term self-renewal constitute an identifiable subpopulation of
tumor cells, much less whether therapeutic targeting of such a
population would effectively control the capacity for therapeuticsubpopulations of tumor cells exhibiting stem cell properties
malignancies. Our findings establish the importance of PTEN
etencies and reveal that individual GBMs can harbor a series
e a range of tumor growth patterns. Importantly, our results
133+ and CD133 cell types that generate highly aggressive
requires effective targeting of multiple self-renewing tumor
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Lineage Hierarchy in GBMresistance and prolonged tumor growth. Here, we examine
heterogeneity of GBM cell competencies for self-renewal and
tumor-initiation and the relationship of these properties to cell
lineage and molecular markers including CD133 expression.
RESULTS
Tumor PTEN Status Correlates with Neurosphere
Growth
We began by examining a series of newly diagnosed GBM cases
to investigate characteristics of tumor cells that are capable of
initiating sustained growth under neural stem cell culture condi-
tions. Twenty-nine newly diagnosed untreated primary GBM
tumors were included in this study (Figure 1D; see Figure S1
and Tables S1 and S2 available with this article online). Using
flow cytometry, we evaluated tumor cells from surgical speci-
mens for both side population behavior and expression of the
stem cell marker CD133. Cells exhibiting side population
behavior were rare (<3%) in all cases examined (Table S2). In
contrast, flow cytometry revealed a wide range in the fraction
of cells expressing CD133 (Figures 1A and 1D), findings that
were consistent with qualitative immunohistochemical evalua-
tion (Figure 1B). Surprisingly, expression profiling revealed that
GBMs of the poor prognosis Mesenchymal subtype (Phillips
et al., 2006) contained fewer CD133+ cells (Figure 1C; Tables
S1 and S3).
We next sought to determine which molecular features of a
tumor correlate with the ability to generate neurosphere cultures.
Although all tumors yielded floating aggregates of viable cells in
neurosphere culture conditions, only about half of the cultures
could be successfully expanded. Cultures that did not increase
in cell number within the first three passages invariably failed
to ever expand and eventually died. With the exception of culture
SF7113, which stopped growing after six passages, all other
expandable lines were stably propagated for at least 20
passages. Comparing features of tumors generating successful
(n = 16) versus failed (n = 13) neurosphere cultures, no differ-
ences were seen in the percentage of CD133+ cells, the
percentage of side population cells, patient age, or relative
frequencies of the following features: patient sex, expression
subtype, MGMT methylation status, p53 mutation, p16 deletion,
PDGFR amplification, and EGFR amplification (p > 0.2 all
comparisons; Figure 1D; Table S2). Patient survival (p = 0.10,
log rank test) and MIB-1 indices (p = 0.11, Student’s t test)
showed trends for correlation with culture outcome (Figure 1D).
In contrast to the features outlined above, tumor PTEN status
showed a significant correlation with neurosphere growth
(Figure 1D; p < 0.05 Fisher’s exact probability test, two-tailed).
Successful lines were derived exclusively from tumors that ex-
hibited loss or mutation of one or both alleles of PTEN. Although
15 of the 23 GBMs with relative copy number loss or mutation of
PTEN formed successful neurosphere cultures, none of the five
GBMs lacking alteration at this locus generated expandable
cultures. Consistent with the hypothesis that loss of PTEN func-
tion is required for neurosphere growth, all neurosphere lines
examined displayed relative loss or mutation at the PTEN locus
on chromosome 10 (Figure 1E) and reduction or absence of
PTEN protein on Western blot (Figure 1F). With one exception,
all neurosphere lines were derived from tumors exhibitingrelative loss of entire chromosome 10 and retained this alter-
ation. The remaining line, SF7101, and its corresponding tumor
displayed homozygous PTEN mutation. All lines and their
respective tumors exhibited gains of chromosome 7p, but
none of the lines derived from patient tumors with EGFR ampli-
fication retained this alteration (Figures 1D and 1E).
Both CD133+ and CD133 GBM Cells Initiate
Neurosphere Growth
To examine the relationship between CD133 expression and the
capacity to initiate neurosphere growth, we utilized fluores-
cence-activated cell sorting (FACS) and magnetic bead separa-
tion to sort CD133+ and CD133 cell fractions (Figure S2). In all
GBMs examined (n = 16), the CD133+ and CD133 fractions of
tumor cells showed qualitatively similar results for neurosphere
growth (i.e., both fractions generated expandable neurospheres
or both yielded failed cultures) (Figure 1D). To quantify differ-
ences in neurosphere initiation capability, we sought to utilize
FACS to determine cloning efficiency; however, repeated efforts
to clone FACS-sorted tumor cells from patient specimens were
unsuccessful. Individual cells (n = 2688) from seven cases
yielded no viable clones, in spite of the finding that successful
cultures were derived from unsorted cells from four of these
cases (Figure 1D). Thus, it appears either that the frequency of
clonogenic cells in patient GBM tumors is very low or that proce-
dures associated with dissociation and FACS sorting of patient
samples significantly compromise cloning efficiency.
As an alternative source of GBMcells enriched for the capacity
to initiate clonal neurosphere growth, we investigated a series of
GBM-derived neurosphere lines. Analysis of these neurosphere
lines revealed substantial variation in the percentage of CD133+
cells, but this percentage remained constant for individual lines
over at least a few passages (Figures 2A and 2C; Figure S3;
Table S4). For clonal analysis, a panel of 14 neurosphere
lines derived from five human GBM tumors was employed
(Figure S1). Included were lines GS-21 and GS-31, (the products
of in vivo passaging neurosphere lines GS-2 and GS-3) (Gunther
et al., 2008), three newly generated neurosphere lines (SF69691,
SF7192, and SF7202), and nine sublines of GS-21 and SF69691.
Using FACS to clone CD133+ and CD133 cells, we observed
that 13 of the 14 lines yielded viable clones (Figure 2C). Although
the panel of lines varied in their frequency of clonogenic cells, no
systematic difference was observed in the clonogenicity of
CD133+ or CD133 cells (Figure 2C) or in the appearance of
expanded cultures derived from them (Figure 2B). Notably,
however, upon dissociation into single cell suspensions, cultures
containing CD133+ cells showed much more aggregation than
cultures lacking CD133+ cells, whether assayed in the presence
(Figure 2D) or absence (data not shown) of the divalent cations
calcium and magnesium.
A Series of Three Clonogenic Cell Types Is Identified
in GBM
Examining a series of expanded clonal cultures, we identified
three clonogenic cell types: Type 1 cells are CD133 cells that
give rise to cultures containing a mixture of CD133+ and
CD133 cells; Type II cells are CD133+ cells that also give rise
to mixed cultures; and Type III cells are CD133 cells that give
rise to cultures of only CD133 cells (Figure 3A). ConsistentCancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc. 363
Figure 1. PTEN Status, but Not CD133 Expression, Correlates with Neurosphere Formation
(A) FACS plots of CD133 expression in a patient GBM (SF7227) with an abundance of CD133+ cells and another case (SF7228) with a paucity of cells labeled for
CD133. CD133-PE signal (y axis) is plotted against autofluorescence in the FITC channel (x axis). In cells stained with antibody to CD133 (right panels), CD133+
(red) and CD133 (blue) cells are identified by a FACS gate (white line) established in corresponding isotype control plots (left panels).
(B) Immunohistochemistry for CD133 in two primary GBM specimens found by FACS to contain either high (SF7227) or low (SF7063) percentages of CD133+
cells. Scale bar, 100 microns and applies to both panels (A) and (B).
(C) A smaller percentage of tumor cells express CD133 inMesenchymal (Mes) subtype tumors compared to other GBMs including Proneural (PN) andProliferative
(Prolif) subtypes and poorly categorized samples (*p = .0007, t test of Mes versus non-Mes).
(D) Characteristics of patient tumors that generate successful (bottom) versus failed neurosphere cultures (top). Summary metrics reported for neurosphere-
forming (Summary NSP+) and failed neurosphere (Summary NSP) patient tumors are mean ± SEM or absolute frequencies. Survival is reported in days;
censored values are indicated by parentheses. PTEN status is reported as wild-type (WT) if no evidence of mutation (MUT) or loss was seen. ND, not determined.
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clones from both tumors SF6969 and GS-2 revealed robust
signal for CD133mRNA in type I and II clones, but very low signal
in type III clones (Figure S4). In total, 177 clones from 11 lines
representing three patient tumors were profiled by FACS for
CD133 expression (Figure 3B). Of the 153 clones for which the
presence or absence of CD133+ cells could be unambiguously
determined, all but two clones could be classified as type I, II,
or III. In total, 25 type I, 67 type II, and 59 type III clones were
identified. No clonal cultures contained 100% CD133+ cells,
and only two CD133+ cells generated cultures lacking CD133+
cells. Thus, type I, II, and III cells appear to account for nearly
all clonogenic cells present in GBM neurosphere cultures.
Not all clonogenic cell types were identified in each of the
cultures for which we determined clone phenotypes; although
type III cells were seen in all but one culture, type II cells were
seen in fewer cultures, and type I cells only occurred in a subset
of the cultures that contained type II cells (Figure 3C). The hier-
archy of clonogenic cell types present in the series of neuro-
sphere lines suggests the possibility of a lineage relationship
between these cell types. Our results demonstrated the pres-
ence of all three clonogenic cell types in two of three tumors
analyzed. Of note, neurosphere line GS-31, which we found to
produce only type III clones, was derived from parental line
GS-3, a line previously reported to contain CD133+ cells
(Gunther et al., 2008). Although line GS-3 has remained positive
for content of CD133+ cells in the laboratory of origin, since
transatlantic transfer as a live culture, this line has consistently
produced cultures and serially transplantable tumors devoid of
CD133+ cells. Thus, it is possible that all three clonogenic cell
types exist in all GBMs generating neurosphere lines, but loss
or irreversible differentiation of type I and II cells can occur.
When maintained in neurosphere media, a substantial fraction
of cells in serial-passaged cultures of type I, II, and III clones from
both GS-2 and SF6969 were immunopositive for the neural stem
cell marker Nestin (Figure 4A). Upon exposure to differentiating
conditions, cultures from all clone types displayed a mixture of
cells labeling for markers of neurons, astrocytes, and oligoden-
droglia (Figures 4B, 4C, and 4D). Hence, all three clonogenic
cell types have the capability in vitro to generate progeny that
express neural stem cell markers and exhibit evidence of multi-
lineage differentiation.
To investigate the self-renewing capacity of the type I, II, and III
clonogenic cell types, we conducted secondary cloning experi-
ments. For these analyses, we utilized primary type I, II, and III
neurosphere clones derived from patient tumors GS-2 and
SF6969. Every clone examined was found to contain cells that
initiate growth of secondary clones similar to the initial clone in
appearance, growth, and CD133 expression. Secondary clones
from CD133+ cells invariably contained a mixture of CD133+ and
CD133 cells, and the percentage of CD133+ cells in theseTumor SF7101 showed homozygous mutation (HOM MUT) associated with isod
designated Y for successful cultures and N for failed cultures. Neurosphere exp
CD133 populations (CD133+ sort, CD133 sort), and single CD133+ and CD
populations, results from FACS sorting are denoted by the superscript 1, and m
(E) Relative DNA copy number estimates of neurosphere lines as determined b
10 except SF7101.
(F) Western blot for PTEN protein reveals reduced signal in neurosphere cultures
PTEN. (See also Tables S1, S2, and S3; Figure S2.)expanded clonal cultures did not differ as a function of the
primary clone type from which the secondary clone was derived
(Figure 3D). In contrast, for secondary clones derived from
CD133 cells, the content of CD133+ cells varied as a function
of the primary clone type, such that type I clones yielded
secondary clones with the highest percentage of CD133+ cells,
type II clones yielded secondary clones with an intermediate
percentage of CD133+, and type III clones yielded secondary
clones containing only CD133 cells (Figure 3D). These findings
are consistent with a lineage hierarchy model in which type III
cells are relatively differentiated cells incapable of producing
CD133+ progeny, whereas both type I and type II cells are
more primordial cell types generating a greater diversity of
progeny.
To assess the capability of each clone type for prolonged
growth in vitro, we selected a series of type I, II, and III clones
derived from patient tumor GS-2 and propagated each line for
greater than 20 passages. No differences in growth rate or
appearance of the lines were observed as a function of clone
type, and all lines continued to show stable propagation for as
long as they were observed. Repeated FACS profiling of these
clonal neurosphere lines revealed that cultures of type III clones
invariably produced only CD133 cells, whereas, with one
exception, all type I and II lines maintained a mixture of
CD133+ and CD133 cells (Figure 3E).
Type I, II, and III Cells Generate Tumors
with Different Growth Kinetics
Having identified the presence of three cell types capable of
long-term propagation and serial clonogencity in vitro, we exam-
ined the ability of progeny from each of these cell types to
generate orthotopic tumors in nude mice. For these studies,
we utilized the same clonal lines derived from patient tumor
GS-2 that were used for long-term in vitro profiling in Figure 3E.
Because tumor SF6969, the second GBM case for which we
identified all three self-renewing cell types, generated a parental
neurosphere line and sublines that were not tumorigenic (data
not shown), we did not examine tumorigenicity of clonal lines
derived from this tumor.
A series of mice, each inoculated in the forebrain with 105 cells
from a GS-2 clonal line, were monitored by magnetic resonance
imaging (MRI) 12 weeks after implantation. Although most mice
grafted with type I or II clones harbored sizeable lesions at this
time point, most mice implanted with type III clones showed no
evidence of tumor (Figures 5A and 5B). Importantly, however,
MRI monitoring at later intervals revealed that all of the clones
eventually generated detectable lesions and, by eight months
after implantation, tumors arose in all mice inoculated that did
not die of unrelated causes (Figure 5A; Table S5). Replicate
grafts of each clone showed a great deal of consistency, and
tumor volumes varied significantly as a function of clone type,isomy of chromosome 10. Ability to form expandable neurosphere cultures is
ansion was determined for unsorted tumor cells (unsorted), bulk CD133+ and
133 cells cloned by FACS (CD133+ clone, CD133 clone). For bulk-sorted
agnetic bead separations by superscript 2.
y array CGH. All lines displayed relative copy number losses of chromosome
(as labeled) compared to LN229, an adherent line homozygous for wild-type
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Figure 2. CD133+ and CD133 GBM Neurosphere Cells Are Equally
Clonogenic
(A) Representative FACS plot of CD133 expression in a neurosphere line
(GS-24). In the right panel, CD133
+ (red) and CD133 (blue) cells of GS-24
are identified by a gate (white line) established using an isotype control plot
of the same culture (left panel).
(B) Clones Expanded from a CD133+ and a CD133 cell from line SF69691.
(C) Clonogenic frequency in a series of neurosphere lines. Percentage of
CD133+ cells in each line is reported, as well as the percentages of CD133+
and CD133 cells cloned by FACS that yielded a neurosphere (freq CD133+,
freq CD133, respectively). *Results from cloning the rare population of cells
residing in the CD133+ sort window are reported even though these two
parental lines and all expanded clones were deemed to have no CD133+ cells.
(D) Dissociated cells from clonal cultures assayed for aggregation in the
presence of calcium and magnesium. Cell aggregates are larger in the culture
containing CD133+ cells (left) compared to containing only CD133 cells
(right). (See also Figure S3 and Table S4.)
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greater than type III (Figure 5B). Histological analysis of mice
killed shortly after MRI demonstrated a good correspondence
for all three clone types between areas quantified as tumor on
T2-weighted MR images and regions of high tumor cell content366 Cancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc.in tissue sections (Figure S5). We next repeated the tumor initia-
tion experiment using a series of type I, II, and III secondary
clones derived from a single primary type I clone. Tumors arose
in all mice inoculated, and the pattern of tumor volumes as a
function of clone type was very similar to that seen in the first
experiment (Figure 5C). Thus, in this experiment with estab-
lished lineage relationships between clonal lines, growth kinetics
vary as a function of clone type. These results show that a single
CD133 cell (type I) is capable of producing phenotypically
distinct progeny (type I, II, or III) that initiate tumors with a
wide range of growth kinetics. Repeated volumetric assess-
ments of grafts from secondary clones revealed that type III
tumors expanded more slowly than did type I or II lesions
(Figure 5D).
Type I, II, and III Clones Support Serial Transplantation
Grafts from type I (n = 2), type II (n = 1), and type III (n = 2) clonal
lines all demonstrated 100% tumorigenicity when serially trans-
planted (Figure 5E; Table S6). For both primary and serial trans-
plants, tumors harvested from mice inoculated with type I or II
lines generated neurosphere cultures that contained a mixture
of CD133+ and CD133 cells, whereas tumors harvested from
grafts of type III lines gave rise to cultures that contained only
CD133 cells (Figure 5F). Thus, each of the three clonogenic
cell types supports self-renewal in vivo, although type III clones
reconstitute more limited aspects of the original tumor.
Type I, II, and III Cells Generate Grafts with Distinct
Histological Features
Histological analysis of grafts arising from the three clone types
revealed distinct features associated with each. Grafts of type III
clones grew with sharp borders between tumor and surrounding
host brain (Figure 6C). Invasion of these grafts occurred as
fingerlike masses of tumor cells projecting into brain paren-
chyma or as tumor cells invading along perivascular spaces
(Figure 6C). In contrast, grafts from type I and II lines displayed
diffuse borders between tumor and brain (Figures 6A and 6B).
These grafts produced single tumor cell infiltrates into both brain
parenchyma and along white matter tracts, and tumor cells were
more rarely seen to invade perivascular spaces. A notable
feature of type I grafts was elongated tumor cells (Figure 6A),
a feature that was significantly more frequent in type I than
type II or III grafts (Figure 6D). Surprisingly, proliferation indices
of type III clone grafts were higher than that of type I grafts
(Figure 6E). None of the grafts displayed evidence of microvas-
cular proliferation, a feature common to all GBMs and especially
prominent inMesenchymal subtype GBMs (Phillips et al., 2006).
Consistent with the histological findings, expression profiling
revealed that none of the clone grafts resembled Mesenchymal
subtype patient tumors and that type III grafts showed more
Proliferative character than type I grafts (Table S7).
Type I, II, and III Cells Generate Grafts with Distinct
Molecular Signatures
Principal component analysis using genes that differed consis-
tently across clone types in GS-2 and SF6969 clonal cultures
revealed that, for both tumors, the first principal component
stratified clones in a continuous fashion such that type I and III
clones populate the ends of a spectrum and type II clones
Figure 3. Three Clonogenic Cell Types Are Identified in GBM Cases
(A) FACS plots of type I, II, and III clones derived from the parental line shown in Figure 2A. Type I and II cells are CD133 and CD133+ cells, respectively, which
gave rise to a mixture of CD133+ and CD133 cells. Type III cells are CD133 cells, which give rise to only CD133 cells.
(B) Frequency of primary clones as a function of the percentage of CD133+ cells in the expanded clonal culture. Blue bars represent clones expanded from
CD133 cells, whereas pink bars represent clones expanded from CD133+ cells.
(C) Frequency of type I, II, and III cells identified in a series of neurosphere lines.
(D) Percentage of CD133+ cells in secondary clones as a function of the cell type cloned. Top panel depicts secondary clones of CD133+ cells cloned from type I
or II primary clones, and bottom panel displays secondary clones expanded from CD133 cells from type I, II, or III primary clones. **p < 0.0005 type III versus I;
*p < 0.05 for both type II versus I and type II versus III (t tests with Holm’s correction for multiple comparisons). Bars represent median values.
(E) Percentage of CD133+ cells in a series of clonal lines assayed at three different in vitro passage (p) numbers. Asterisk denotes a type II line that became
negative for CD133+ cells after passage 21. Less than 1% CD133+ cells were seen for all type III clonal lines (n = 6) at all passages. (See also Figure S4.)
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Figure 4. Type I, II, and IIIClonesSupportMultilineageDifferentiation
(A) Whenmaintained in neurosphere growth conditions, type I, II, and III clones
from both GS-2 and SF6969 display a substantial fraction of cells expressing
Nestin.
(B–D) Under differentiating conditions, all clonal cultures contain cells that
label for GFAP, TUJ1, andGalC (as indicated). SF6969 clonal cultures exposed
to differentiation media produced a predominance of TUJ1+ cells along with
smaller numbers of GFAP+ and GalC+ cells, whereas GS-2 clones produced
substantial numbers of both GFAP+ and TUJ1+ cells and smaller numbers
of GalC+ cells. For (A)–(D), bar in upper left panel is 0.025 mm, green signal
represents immunopositivity, and blue signal is DAPI nuclear counterstain.
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Figure S6A). Analysis of grafts from GS-2 revealed that, once
again, the type II clones were intermediate between extremes
set by type I and III clones (Figures S6B and S6C). These findings
are consistent with a lineage model in which type I cells are the368 Cancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc.most primitive progenitor for self-renewing cell types in GBM
and type III cells are the most differentiated self-renewing cell
type (Figure 8).
For GS-2 clones, differences in gene expression as a function
of clone type were notably more robust in grafts than cultures
(Table S8). One gene most differentially expressed among graft
types is FABP7 (or BLBP), a radial glial marker that has been
previously associated with invasiveness and poor outcome in
GBM (Kaloshi et al., 2007; Liang et al., 2006) and that is a marker
of tumor-initiating cells in ependymoma (Taylor et al., 2005).
Grafts of both type I and II clones express high levels of
FABP7, whereas expression in type III grafts is much lower
(Figure 7C). Immunohistochemistry confirmed strong expression
of FABP7 in grafts of type I and type II clones, and, within these
grafts, expression was particularly intense in elongated invading
tumor cells (Figure 5A), which presented images resembling
radial glia. Comparing expression of a series of markers of neural
stem cells (Ghashghaei et al., 2007; Noctor et al., 2007) in type I
versus type III grafts, we find that type I grafts express higher
levels of FABP7, Nestin, GLAST, and Vimentin and show a
nonsignificant trend for overexpression of SOX2 (Figure 7C). In
contrast, type III grafts show significantly higher expression of
markers of intermediate progenitors (Iulianella et al., 2008; Nieto
et al., 2004; Noctor et al., 2007) including TBR2, DLX2, DLX1,
and CUTL2, (Figure 7D). For markers of both neural stem cells
and intermediate progenitors, type II grafts typically showed
expression values that fell within the extremes set by type I
and III grafts (Figures 7C and 7D).
DISCUSSION
The current investigation relates heterogeneity of GBM cell
capabilities to cell lineage and molecular markers, including
but not limited to, CD133 expression. Our results indicate that
PTEN status and cell lineage appear to be key determinants of
GBM cell capabilities and reveal that individual GBMs can
contain a series of self-renewing tumor-initiating cells that exhibit
a range of phenotypic markers and in vivo growth patterns.
Previous studies have indicated that neurosphere cultures
grow from only a subset of GBMs (Galli et al., 2004; Gunther
et al., 2008), and that the ability to generate successful neuro-
sphere lines is negatively correlated with patient survival time
(Pallini et al., 2008). These studies suggest that specific molec-
ular subtypes of GBM are enhanced in the ability to grow in
neural stem cell culture conditions, but they do not provide
insight into the molecular determinants of this competency. Of
the characteristics we examined in a series of newly diagnosed
GBM cases, PTEN deficiency was the only statistically signifi-
cant correlate of successful neurosphere propagation. Although
nearly two-thirds of the PTEN-deficient cases in our study gener-
ated expandable neurosphere lines, none of the five GBMs with
both PTEN loci intact generated successful cultures. These
results suggest that PTEN insufficiency may be required to
facilitate GBM cell growth in neurosphere conditions, but the
failure of some PTEN-deficient GBMs to generate successful
cultures may indicate necessity of additional molecular determi-
nants. Our finding that PTEN-deficient GBM tumors are
enhanced for the ability to propagate neurosphere lines is paral-
leled by findings that PTEN deletion enhances self-renewal and
Figure 5. Clone Types Generate Orthotopic Grafts with Different Growth Kinetics
(A) Representative MR images show that grafts of type I and II clones are visible at 12 weeks after implantation, whereas lesions from type III clones are typically
not apparent at 12 weeks and small at 24 weeks. Blue pseudocoloring highlights tumor area.
(B) At 12 weeks after implantation, tumor volumes are smaller for type III grafts than either type I or type II grafts (*p < 0.05 for both comparisons, Bonferroni
corrected p values from Wilcoxon two-sample exact tests). For (B)–(D), results from replicate mice (n = 2 or 3) are displayed by symbols of the same color,
and bars indicate median values.
(C) For a series of secondary clones derived from one primary type I clone, tumor volumes at 12 weeks after implantation are smaller for grafts of type III clones
than grafts of either type I or type II clones (*p < 0.00005 for both comparisons, Bonferroni corrected t tests; p < 0.00001 for overall effect of clone type, F-test from
linear mixed model).
(D) Type III grafts expand more slowly than do type or type II grafts (*p < 0.0005 for both I versus III and II versus III, Bonferroni corrected t tests; p < 0.00005 for
overall clone effect, F-test from a linear mixedmodel). Expansion index represents the fold change in tumor volumes over a six-week period. Measurements were
initiated at six weeks for type I and II grafts and 12 weeks for type III grafts.
(E) Representative MR images of serial transplants of two type I clones, one type II clone, and two type III clones.
(F) Percentage of CD133+ cells in neurosphere lines prior to implantation (preimplant) or following the first or second in vivo passage (ivp1, ivp2). A mixture of
CD133+ and CD133 cells was derived from type I and II grafts, whereas type III grafts (n = 4) generated exclusively CD133 cells. (See also Tables S5 and
S6 and Figure S5.)
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(Gregorian et al., 2009; Groszer et al., 2001) and cooperates
with p53 loss in neural stem cells to promote an undifferentiated
state with high renewal capacity and tumorigenic potential
(Zheng et al., 2008). Additional support for the role of PTEN
status in determining GBM cell capabilities comes from a series
of reports demonstrating that PTEN deletion enhances the
formation of aggressive high-grade lesions and neurosphere-
forming capacity in genetically engineered mouse models of
glioma (Bleau et al., 2009; Kwon et al., 2008; Wei et al., 2006;
Xiao et al., 2002). Of note, haploinsufficiency of PTEN is sufficient
to drive effects in both neural stem cells and glioma models
(Groszer et al., 2001; Kwon et al., 2008; Xiao et al., 2002).
Our observations of patient tumors indicate that the frequency
of GBM cells expressing the stem cell marker CD133 does not
correlate with the ability of dissociated cells from a tumor to
grow in neurosphere culture conditions. The finding that GBMs
of the poor prognosisMesenchymal expression subtype contain
fewer CD133+ cells is similar to that of a recent report (Joo et al.,2008), and suggests the possibility that the poor prognosis of
some GBMs may be related to tumor growth that is not fueled
by CD133+ cells. This suggestion is supported by our clonal
analysis revealing populations of GBM-derived CD133 cells
that support long-term growth and self-renewal in vitro and
can initiate serially transplantable tumors.
Amajor finding of the current investigation is that both CD133+
and CD133 cells from the same GBM tumor can exhibit
self-renewal in vitro and the capability to generate serially trans-
plantable tumors in immunocompromised mice. Our findings
confirm both the observation that CD133 is a marker for self-
renewing tumor-initiating GBM cells (Singh et al., 2004) and the
suggestion that, in some instances, CD133 cells can share
these properties and even give rise to CD133+ cells (Beier
et al., 2007; Ogden et al., 2008; Wang et al., 2008). Our observa-
tion that dissociates of cultures derived from CD133+ cells show
greater aggregation than suspensions of cultures containing only
CD133 cells indicate that caution should be exerted in inter-
preting the behavior of bulk-sorted cell populations. By utilizingCancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc. 369
Figure 6. Clone Types Generate Grafts with Distinct Histologies
Histology of type I (A), type II (B), and type III (C) clone grafts. Stains depicted are hematoxylin and eosin (H&E), as well as immunohistochemistry for Ki67, FABP7,
and Vimentin (VIM). Scale bars in (A) are 0.05 mm and pertain to corresponding panels in (B) and (C).
(D) Type I grafts have a greater fraction of elongated cells than do either type II or III grafts (*p < 0.005 for both comparisons, t tests with Bonferroni correction;
p < 0.0005 overall effect of clone type, F-test from a linear mixed model).
(E). Type III grafts have a greater fraction of Ki67 positive cells than do type I grafts (*p < 0.05, Bonferroni corrected t test; p < 0.01for overall clone effect,
F-test from a linear mixed model). Bars in (D) and (E) indicate median values and results from replicate mice are displayed by symbols of the same color.
(See also Table S7.)
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capabilities of individual tumor cells and their progeny.
The model we propose (Figure 8) on the basis of our clonal
analysis suggests that patient tumors contain multiple distinct
populations of lineally related CD133 cells representing
different stages of differentiation: type I cells (which generate
aggressive tumors comprising a mixture of CD133+ and
CD133 cells), type III cells (which give rise to slow-growing
circumscribed lesions of CD133 cells), and a third population
of CD133 cells that does not thrive under neurosphere condi-
tions and may not be tumorigenic. Differences in the proportions
of these populations of CD133 cells between patient tumors
could provide an explanation for the discrepancies among
previous reports about the abilities of CD133 cells isolated
directly from patient tumors or xenografts to form neurospheres
or tumors (Beier et al., 2007; Joo et al., 2008; Ogden et al., 2008;
Singh et al., 2004; Wang et al., 2008). Importantly, our model
predicts that relative enrichment of self-renewing tumor-initi-
ating cell types in neurosphere culture allows these cultures to
reveal populations of self-renewing CD133 cells that could be
masked by differentiated populations of CD133 cells present
in bulk-sorted CD133 cell fractions from patient tumors. Addi-
tional studies are needed to determine whether all self-renewing370 Cancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc.cell types we report occur in all patient tumors and to determine
molecular markers that are unique to subclasses of CD133
GBM cells with differing competencies.
Although alternatemodels are plausible, several sets of obser-
vations support the idea that type I, II, and III cells constitute
a lineage of self-renewing cells wherein type I and III cells (both
of which are CD133) represent the most primordial and differ-
entiated states, respectively (Figure 8). Specifically, type II
clones are intermediate between the extremes set by type I
and III clones in the following features: (1) presence of the cell
types across the series of neurosphere lines investigated; (2)
percentage of CD133+ cells in secondary clones derived from
CD133 cells; (3) growth kinetics of orthotopic grafts; (4)
frequency of elongated tumor cell profiles in grafts; and (5)
gene expression profiles. Although the model we propose
suggests that type I cells represent progenitors of type II cells,
our data do not allow us to distinguish between this possibility
and one in which type I and II cells represent inter-convertible
phenotypic states of the same cell population. The demonstra-
tion that CD133 expression can vary as a function of cell cycle
(Jaksch et al., 2008) suggests the possibility that type I and II
cells might represent different stages of a single cell type. This
suggestion is not, however, consistent with the observed
Figure 7. Clone Types Display a Spectrum of Gene Expression
(A and B) Principal component analysis for cultures of clones fromGS-2 (A) or SF6969 (B) stratifies clone types as a function of the first principal component (PC1).
Analysis was performed using a list of 156 genes whose expression changed coordinately across clone types from both tumors. Similar results were seen if
clustering was performed with greater numbers of genes (Figure S6). Orange, pink, and blue symbols represent type I, II, and III clone grafts, respectively.
(C) Expression of four out of five neural stem cell markers is higher in type I grafts than type III grafts.
(D) Intermediate progenitor markers are more highly expressed in type III versus type I grafts. For (C) and (D), *p < 0.05, **p < 0.005, and ***p < 0.0005, for type I
versus type III. (See also Figure S6 and Table S8.)
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generated from type I and II clone types. Regardless of the exact
relationship between type I and II cell types, our data provides
compelling evidence that type I cells represent a population of
CD133 cells that is capable of generating a mixture of
CD133+ and CD133 cells in vitro and, in at least the one GBM
case tested, is highly tumorigenic. In addition, our data clearly
demonstrate that type I and II cells, both of which produce
CD133+ and CD133 cells, are progenitors for type III cells, a
population of self-renewing cells that produces only CD133
cells.
In the grafts of clonal lines from patient tumor GS-2, we
observed striking differences in growth patterns and gene
expression as a function of clone type. Gene expression patterns
of grafts stratified clones by type, but did so in a continuous
fashion. Although differences in gene expression between clone
types were more modest in vitro, the expression of genes that
varied consistently across clone types stratified cultures of
both GS-2 and SF6969 clones in a pattern similar to that seen
for the grafts. These findings suggest that each clone may
generate progeny that tend to persist at a particular stage along
a differentiation hierarchy and that the self-renewing cell types
we describe each represent a range along a continuum of
phenotypes. Of particular interest is our finding that both type I
and type II clonal lines generate rapidly growing invasive grafts
that express radial glial markers including FABP7, whereas
grafts of type III clonal lines give rise to slow-growing circum-scribed lesions that express markers of intermediate progeni-
tors, a more differentiated cell type in the forebrain neural
lineage. These findings are consistent with previous reports
that link FABP7 to invasive behavior and poor prognosis in
GBM (Kaloshi et al., 2007; Liang et al., 2006) as well as to prolif-
eration and maintenance of stem cell phenotype in forebrain
development (Arai et al., 2005). Because markers of human fore-
brain lineage have not been thoroughly described, the ability to
explore parallels between the phenotype of our clone type grafts
and cell types in human forebrain lineage is limited; hence, our
conclusions relating clone types to differentiation are tentative.
An important limitation of the current study is that our analysis
of self-renewing cell types in GBM pertains only to the subset of
GBMs containing cells that can be propagated in neurosphere
culture conditions. Recent work in a mouse model of medullo-
blastoma indicates tumor-propagating capabilities of cells that
lack neurosphere-generating capacity (Read et al., 2009).
Hence, our observations do not preclude the possibility that
cell types capable of long-term self-renewal and tumor initiation
in vivo were not identified in our study. In particular, we note that
none of the orthotopic neurosphere grafts in this study or in our
previous work (Gunther et al., 2008) reconstitute tumors with
microvascular proliferation or aMesenchmyal signature. In addi-
tion, we cannot say to what extent our observations on tumor
growth properties for type I, II, and III clonal lines derived from
patient tumor GS-2 are representative of the behavior of self-
renewing cell types from other patient tumors. Our observationsCancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc. 371
Figure 8. Lineage Hierarchy Model of Type I, II, and III Cell Types
The model depicted in the upper portion of this figure demonstrates how clonogenic cell types present in neurosphere lines may relate to cell types in patient
tumors, whereas the lower portion of the figure is a schematic summary of data from clonal analysis of tumors GS-2, GS-3, and SF6969. (See also Figure S1.)
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contain a hierarchy of self-renewing tumor cells capable of
promoting growth of a spectrum of serially transplantable tumor
phenotypes.
It is important to recognize that the current results relating cell
lineage to tumor cell capabilities pertain to relationships among
cells of established tumors and do not speak to the issue of cell
type of origin for GBM. Results from genetically engineered
models have demonstrated that medulloblastomas or gliomas
can be driven by the introduction of mutations into either neural
stemcells or lineage committed cell types, and that tumor pheno-
types can be very similar for tumors arising from these different
cell types (Dai et al., 2001; Read et al., 2009; Schuller et al.,
2008; Uhrbom et al., 2002; Yang et al., 2008). Recent results
from a somatic tumor suppressor model of astrocytoma provide
clear evidence that lesions arising frommanipulated neural stem
cell/progenitors generate both tumor cells expressing neural
stem cell markers as well as tumor cells expressing markers of
both differentiated neuronal and glial lineages (Alcantara Llaguno
et al., 2009). Interestingly, transplantation experiments of a
medulloblastoma model convincingly demonstrate that cells
expressing the progenitor marker CD15, but not the neural
stem cell marker CD133, are capable of tumor propagation
(Read et al., 2009). Thus, although the phenotype of cells present
in a tumor may not be a direct reflection of cell type of origin, in at
least some instances, tumor cell capabilities do appear to vary as
a function of lineage relationships among tumor cells.
Our findings add to the growing body of evidence that lineage
relationships of cells within a solid human tumor can be an
important determinant of tumor cell competencies, but suggest
that cells expressing a range of differentiation markers can
contribute to the relentless and aggressive growth of individual
malignancies. These findings predict that therapeutic ap-
proaches targeting individual stem cell markers may confer
limited benefit and provide impetus for strategies to address
phenotypically diverse populations of self-renewing tumor cells.EXPERIMENTAL PROCEDURES
Patient Tumors
This study was approved by the Committee on Human Research of the Univer-
sity of California San Francisco, and all patients signed an approved consent
document prior to surgery. Surgical specimens of tumors were examined
by a neuropathologist to verify that each case met WHO criteria for GBM
and to select a tissue fragment with high content of viable tumor tissue.
Each tissue specimen was minced into 1 mm3 cubes and maintained in sterile
saline at room temperature. Two to four cubes of the mincate were frozen on
dry ice for extraction of RNA and DNA, and the remaining tissue was dissoci-
ated into a single cell suspension in media containing 0.2% collagenase,
0.01% hyaluronidase, and 0.002% DNaseI at 37C for 30 to 60 min or at
room temperature overnight.Neurosphere Cultures
Neurosphere cultures were maintained in neurosphere culture medium
(see Supplemental Experimental Procedures) in 3% oxygen and were
passaged by trituration in nonenzymatic dissociation solution (Sigma,
C-5914). All cultures were passaged when spheres reached approximately
200–300 microns in diameter, and cell counts were performed at the time of
passage. For cultures passaged at intervals longer than one week, media
containing fresh growth factors was added twice weekly.To establish neurosphere cultures, dissociated tumor cells were seeded at
an initial density of 1–5 3 105/ml. Sorted populations from each tumor case
were matched for plating density.
FACS Analysis, Sorting, and Cloning
CD133 expression was monitored by use of CD133/1 Ab-PE (Miltenyi, cat. no.
130-080-801) either alone or in combination with CD133/2 Ab-PE (Miltenyi,
cat. no. 130-090-853). For FACS analysis, all patient samples were analyzed
within 24 hr of surgery and all cultures were analyzed at 6 days (±1 day) after
passaging. FACS cloning was performed with a FACSAria sorter (BD Biosci-
ences, San Jose, CA; see Figure S3). For each case, single cells were depos-
ited into 192 wells of two 96-well plates. Microscopic examination confirmed
that representative wells contained a single cell. Clones were scored by visual
inspection of all wells at 3 to 4 weeks after seeding. Cutoff values of <1%
and >10% were used for determination of absence and presence, respec-
tively, of CD133+ cells.
Western Blot
Six neurosphere lines and two adherent GBM lines, LN229 and U87 MG, were
examined using PTEN antibody fromCell Signaling Technology (Danvers,MA).
Cell Aggregation Assays
Cells were suspended at a concentration of 23 106/ml in Hank’s balanced salt
solution containing 10 mM HEPES (pH 7.5), 1% bovine serum albumin, and
either 1 mM calcium chloride plus 1 mM magnesium sulfate or 2 mM EDTA;
0.5 ml of cell suspensions were placed into wells of a 24-well culture plate
and rotated on a gyratory shaker (100 rpm) at 37C for 2 hr. Aggregation
was terminated by the addition of 4% glutaraldehyde.
Differentiation of Clonal Cultures and Immunocytochemistry
To differentiate clonal neurosphere lines, dissociated cells were plated in
eight-chamber slides at 5000 cells per well for 5 days in the neurobasal media
(Invitrogen) supplemented with fetal bovine serum (10%; Sigma), B27 (13;
Invitrogen), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin
(100 ml/ml; Invitrogen), dB-cAMP (100 mM; Sigma), and all-trans retinoic acid
(0.5 mM; Sigma). For immunocytochemistry, primary antibodies were mouse
anti-Nestin (1:200; Millipore), mouse anti-GalC, (1:150; Millipore), mouse
anti-TUJ1 (1:1000; Covance), and mouse anti-GFAP-Alexa 488 (1:200; R&D
System).
Orthotopic Grafts
Neurosphere cells (105) in 5 ml of Hanks balanced salt solution (Invitrogen) were
stereotactically implanted unilaterally into the striatum ofmale CD1 nudemice.
T2-weighted MR images were obtained using a 9.4-T magnet (Varian), and
tumor volumes were calculated from resulting images using MRVision 1.5
software (Menlo Park, CA) by an observer blinded to experimental group.
For serial transplantation, grafts were harvested and expanded for 1 to 2weeks
in neurosphere culture conditions prior to reimplantation. These studies were
performed with the approval of Genentech’s Institutional Animal Care and Use
Committee. Genentech is accredited by AAALAC International, registered with
the USDA, and follows the ILAR Guide for the Care and Use of Laboratory
Animals.
Histology and Image Analysis
Histological analyses were performed on formalin fixed paraffin-embedded
tissue sections. Antibodies for immunohistochemistry were as follows:
CD133 (AbCam), FABP7 (AF3166 R&D Systems), Ki67 (M7240 Dako), and
human Vimentin (AB8979, AbCam). MIB-1 indices in patient specimens (frac-
tion Ki67+ tumor cells) were determined by a neuropathologist using standard
techniques. For quantification of the fraction of elongated and Ki67+ cells in
grafts, a modified TissueMap solution in Definiens Developer (version 7.0.4)
was used to sample all nuclei present in the tumor tissue of one tissue section
per animal.
DNA Analysis and Expression Profiling
DNA from patient tumors was profiled for copy number changes on Affymetrix
500k chips and sequenced for mutations in exons 4–8 of p53 and exons 5 and
6 of PTEN. DNA from neurosphere lines was analyzed for copy numberCancer Cell 17, 362–375, April 13, 2010 ª2010 Elsevier Inc. 373
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was extracted as described elsewhere (Phillips et al., 2006) and profiled on
Agilent WHG (for patient samples) or WHG 43 44 chips (for neurosphere lines
and grafts) according to the manufacturer’s (Agilent technologies, Palo Alto
CA) protocol. Proneural, proliferative, and mesenchymal GBM subtypes
were determined by k means clustering of expression data from the Agilent
WHGplatform using amodification of the previously published 35 genemarker
list (Phillips et al., 2006) (Table S1B). Principal component analysis was per-
formed using Spotfire Decision Site software. For principal component anal-
ysis of SF6969 and GS-2 clonal cultures, probe sets (n = 156) included in
the analysis were derived from a two-way ANOVAwith tumor source and clone
type as additive effects, implemented to detect common and significant (at
a FDR of 1%) shifts across three clone types in both tumor sources studied.
Statistical Analysis
An alpha value of 0.05 was adopted for all analyses. All tests were two-tailed
and corrected for multiple comparisons as appropriate. Details of the number
of replicate observations and of statistical analysis are included in Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
Microarray data have been deposited at GEO under accession number
GSE19612.
SUPPLEMENTAL INFORMATION
Supplemental information includes six figures, eight tables, and Supplemen-
tal Experimental Procedures and may be found with this article online at
doi:10.1016/j.ccr.2009.12.049.
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